Methylated Septin 9 Blood Test Kit (Epi proColon) for Colorectal Cancer Screening

February 24, 2017 | Technology Forecasts


Note: The following ratings and comments reflect the opinions and consensus of an expert panel convened by ECRI Institute to review information on this topic.

Anticipated Utilization: 3(Expected to be used by 40% to 60% of eligible patients)

More than 20 million Americans remain unscreened despite being classified as at-risk for colorectal cancer (CRC) or meeting criteria for CRC screening, according to the U.S. Centers for Disease Control and Prevention (CDC). Adler et al. (2014) suggest that many people who are ineligible for colonoscopy or do not wish to have screening using fecal occult blood testing but are recommended to have CRC screening could choose Epi proColon® (Epigenomics AG, Berlin, Germany). Up to 10 million people might use the test if it can promote screening in half of eligible individuals.

Estimated Adoption Status: 3 (Early adoption occurring – 0% to...

Access Full Content

Contact us today at 610.825.6000.